[No influence of imatinib on type 2 diabetes].
Five patients with type 2 diabetes, three of them treated with insulin and two with oral antidiabetic drugs, receiving imatinib due to chronic myeolid leukaemia are reported. Treatment with imatinib 400 mg/day for 7 to 37 (mean 24.2) months had no positive effect on clinical course of type 2 diabetes.
Chodorowski
Zygmunt
Z
Katedra i Klinika Chorób Wewnetrznych, Geriatrii i Toksykologii Klinicznej, Akademii Medycznej w Gdańsku.
Sein Anand
Jacek
J
Hellmann
Andrzej
A
Prejzner
Witold
W
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage; D001549:Benzamides; D001786:Blood Glucose / Q000378:metabolism; D048909:Diabetes Complications / Q000139:chemically induced; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000188:drug therapy; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000068877:Imatinib Mesylate; D007328:Insulin / Q000008:administration & dosage; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications* / Q000188:drug therapy*; D008297:Male; D008687:Metformin / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage*; D011743:Pyrimidines / Q000008:administration & dosage*
D000970:Antineoplastic Agents; D001549:Benzamides; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D008687:Metformin